• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

LI-RADS 版本 2018 对 CT 用于确定高肝癌风险患者符合米兰标准的肝移植资格的性能。

Performance of LI-RADS Version 2018 on CT for Determining Eligibility for Liver Transplant According to Milan Criteria in Patients at High Risk for Hepatocellular Carcinoma.

机构信息

Department of Radiology, Seoul National University Hospital, 101 Daehak-ro, Jongno-gu, Seoul 03080, Republic of Korea.

Department of Radiology, Seoul National University College of Medicine, Seoul, Republic of Korea.

出版信息

AJR Am J Roentgenol. 2022 Jul;219(1):86-96. doi: 10.2214/AJR.21.27186. Epub 2022 Feb 9.

DOI:10.2214/AJR.21.27186
PMID:35138137
Abstract

LI-RADS has been investigated primarily in terms of detection of hepatocellular carcinoma (HCC), with less attention given to its performance, particularly on CT, in determining eligibility for liver transplant (LT). The purpose of our study was to assess the performance of LI-RADS version 2018 (v2018) on CT for the diagnosis of HCC and determination of LT eligibility according to the Milan criteria (MC). This retrospective study included 136 patients (110 men, 26 women; mean age, 53.9 ± 8.1 [SD] years) at high-risk for HCC who underwent liver protocol CT within 3 months before LT between January 2010 and December 2018. Two radiologists independently reviewed CT examinations using LI-RADS v2018; Organ Procurement and Transplantation Network (OPTN) classes were constructed from the LI-RADS interpretations. Histopathologic analysis of liver explants served as the reference standard for determining the presence of HCC and LT eligibility based on MC. Diagnostic performance was evaluated. Overall survival (OS) was assessed based on medical record review. Based on histopathologic evaluation of liver explants in the 136 patients, 27 patients had no malignancy, 77 were eligible for LT due to HCC within MC, and 32 were unsuitable for LT (i.e., HCC beyond MC in 16 patients, HCC with macrovascular invasion in 12, non-HCC malignancy in four). LR-5 exhibited per-lesion sensitivity and PPV for HCC of 55.9% and 92.8%, respectively, for reader 1 and 39.8% and 86.5% for reader 2. When considering LR-5 observations to represent HCC in assessing MC, LI-RADS had accuracy for determining LT eligibility of 92.7% for reader 1 and 85.3% for reader 2; OPTN criteria had accuracy for determining LT eligibility of 89.0% for reader 1 and 84.4% for reader 2. Five-year OS for patients within MC versus 5-year OS for patients unsuitable for LT was 92.2 months versus 56.0 months for LI-RADS, 92.6 months versus 47.6 months for OPTN criteria, and 93.3 months versus 55.1 months for histopathologic assessment of liver explants. LI-RADS v2018, as evaluated on CT in high-risk patients, shows high PPV for HCC detection and high accuracy for determining LT eligibility based on MC. LT eligibility based on preoperative LI-RADS evaluation is associated with post-LT survival. These findings support the use of LI-RADS on CT in assessing eligibility in patients who are candidates for LT.

摘要

LI-RADS 主要针对肝细胞癌(HCC)的检测进行了研究,而对其在确定是否符合米兰标准(MC)以进行肝移植(LT)方面的表现关注较少。本研究的目的是评估 LI-RADS 2018 版(v2018)在 CT 上对 HCC 的诊断和根据 MC 确定 LT 资格的性能。这项回顾性研究纳入了 2010 年 1 月至 2018 年 12 月期间因 HCC 风险较高而在 LT 前 3 个月内接受肝脏协议 CT 检查的 136 例患者(110 例男性,26 例女性;平均年龄 53.9±8.1[SD]岁)。两名放射科医生独立使用 LI-RADS v2018 对 CT 检查进行了评估;根据 LI-RADS 解读构建了器官获取和移植网络(OPTN)分类。对肝脏标本的组织病理学分析作为确定 HCC 存在和根据 MC 确定 LT 资格的参考标准。评估了诊断性能。根据病历评估了 136 例患者的总生存率(OS)。基于对 136 例患者肝脏标本的组织病理学评估,27 例患者无恶性肿瘤,77 例患者符合 MC 范围内的 LT 标准,32 例患者不符合 LT 标准(即 16 例患者的 HCC 超出 MC,12 例患者的 HCC 伴大血管侵犯,4 例患者的非 HCC 恶性肿瘤)。读者 1 和读者 2 的 LR-5 对 HCC 的病变内敏感性和阳性预测值(PPV)分别为 55.9%和 92.8%,读者 2 的 LR-5 为 39.8%和 86.5%。当考虑将 LR-5 观察结果视为 MC 中 HCC 的代表时,LI-RADS 确定 LT 资格的准确性为读者 1 的 92.7%,读者 2 的 85.3%;读者 1 的 OPTN 标准确定 LT 资格的准确性为 89.0%,读者 2 的准确性为 84.4%。MC 范围内的患者与不适合 LT 的患者的 5 年 OS 分别为 LI-RADS 的 92.2 个月与 56.0 个月,OPTN 标准的 92.6 个月与 47.6 个月,肝脏标本组织病理学评估的 93.3 个月与 55.1 个月。在高危患者的 CT 上评估的 LI-RADS v2018 版显示 HCC 检测的高 PPV 和基于 MC 确定 LT 资格的高准确性。基于术前 LI-RADS 评估的 LT 资格与 LT 后的生存相关。这些发现支持在评估 LT 候选患者的资格时在 CT 上使用 LI-RADS。

相似文献

1
Performance of LI-RADS Version 2018 on CT for Determining Eligibility for Liver Transplant According to Milan Criteria in Patients at High Risk for Hepatocellular Carcinoma.LI-RADS 版本 2018 对 CT 用于确定高肝癌风险患者符合米兰标准的肝移植资格的性能。
AJR Am J Roentgenol. 2022 Jul;219(1):86-96. doi: 10.2214/AJR.21.27186. Epub 2022 Feb 9.
2
Intraindividual Comparison of Contrast-Enhanced Ultrasound Using Perfluorobutane With Modified Criteria Versus CT/MRI LI-RADS Version 2018 for Diagnosing HCC in High-Risk Patients.应用改良标准对比增强超声造影与 CT/MRI LI-RADS Version 2018 对高危人群 HCC 进行诊断的个体内比较。
AJR Am J Roentgenol. 2023 May;220(5):682-691. doi: 10.2214/AJR.22.28420. Epub 2022 Nov 16.
3
Suboptimal performance of LI-RADS v2018 on gadoxetic acid-enhanced MRI for detecting hepatocellular carcinoma in liver transplant candidates.LI-RADS v2018 对钆塞酸增强 MRI 检测肝移植候选者肝细胞癌的性能不佳。
Eur Radiol. 2024 Jan;34(1):465-474. doi: 10.1007/s00330-023-10014-6. Epub 2023 Aug 3.
4
Diagnostic Performance of LI-RADS Version 2018, LI-RADS Version 2017, and OPTN Criteria for Hepatocellular Carcinoma.LI-RADS 版本 2018、LI-RADS 版本 2017 和 OPTN 标准用于诊断肝细胞癌的性能比较。
AJR Am J Roentgenol. 2020 Nov;215(5):1085-1092. doi: 10.2214/AJR.20.22772. Epub 2020 Sep 2.
5
Comparison of international guidelines for diagnosis of hepatocellular carcinoma and implications for transplant allocation in liver transplantation candidates with gadoxetic acid enhanced liver MRI versus contrast enhanced CT: a prospective study with liver explant histopathological correlation.比较国际指南对肝细胞癌的诊断标准,以及钆塞酸增强 MRI 与对比增强 CT 在肝移植候选者中的应用,对肝移植候选者的移植分配的影响:一项前瞻性研究与肝切除组织病理学相关性。
Cancer Imaging. 2022 Oct 4;22(1):55. doi: 10.1186/s40644-022-00497-9.
6
Optimal criteria for hepatocellular carcinoma diagnosis using CT in patients undergoing liver transplantation.应用 CT 对肝移植患者进行肝细胞癌诊断的最佳标准。
Eur Radiol. 2019 Feb;29(2):1022-1031. doi: 10.1007/s00330-018-5557-1. Epub 2018 Jul 4.
7
Hepatocellular carcinoma (HCC) versus non-HCC: accuracy and reliability of Liver Imaging Reporting and Data System v2018.肝细胞癌(HCC)与非 HCC:肝脏影像报告和数据系统 v2018 的准确性和可靠性。
Abdom Radiol (NY). 2019 Jun;44(6):2116-2132. doi: 10.1007/s00261-019-01948-x.
8
Evaluation of LI-RADS Version 2018 Treatment Response Algorithm for Hepatocellular Carcinoma in Liver Transplant Candidates: Intraindividual Comparison between CT and Hepatobiliary Agent-enhanced MRI.LI-RADS 版本 2018 肝细胞癌治疗反应算法在肝移植候选者中的评估:CT 和肝胆期增强 MRI 的个体内比较。
Radiology. 2021 May;299(2):336-345. doi: 10.1148/radiol.2021203537. Epub 2021 Mar 2.
9
Prospective evaluation of Gadoxetate-enhanced magnetic resonance imaging and computed tomography for hepatocellular carcinoma detection and transplant eligibility assessment with explant histopathology correlation.前瞻性评估钆塞酸增强磁共振成像和计算机断层扫描在肝细胞癌检测和移植适应证评估中的作用,并与离体组织病理学进行相关性分析。
Cancer Imaging. 2023 Feb 25;23(1):22. doi: 10.1186/s40644-023-00532-3.
10
Evaluation of treatment response in hepatocellular carcinoma in the explanted liver with Liver Imaging Reporting and Data System version 2017.采用 2017 版肝脏影像报告和数据系统评估肝移植术后肝癌患者的治疗反应。
Eur Radiol. 2020 Jan;30(1):261-271. doi: 10.1007/s00330-019-06376-5. Epub 2019 Aug 15.

引用本文的文献

1
Lessons learned: strategies for implementing and the ongoing use of LI-RADS in your practice.经验教训:在实践中实施和持续使用肝脏影像报告和数据系统(LI-RADS)的策略。
Abdom Radiol (NY). 2025 May;50(5):2053-2065. doi: 10.1007/s00261-024-04643-8. Epub 2024 Oct 23.
2
Performance of LI-RADS category 5 vs combined categories 4 and 5: a systemic review and meta-analysis.LI-RADS 类别 5 与类别 4 和 5 联合的表现:系统评价和荟萃分析。
Eur Radiol. 2024 Nov;34(11):7025-7040. doi: 10.1007/s00330-024-10813-5. Epub 2024 May 29.
3
Hepatocellular Carcinoma: Optimal Radiological Evaluation before Liver Transplantation.
肝细胞癌:肝移植前的最佳影像学评估
Life (Basel). 2023 Nov 27;13(12):2267. doi: 10.3390/life13122267.
4
Liver Imaging Reporting and Data System (LI-RADS) v2018: differential diagnostic value of ADC values for benign and malignant nodules with moderate probability (LR-3).肝脏影像报告和数据系统(LI-RADS)v2018:表观扩散系数(ADC)值对中度可能性(LR-3)的良性和恶性结节的鉴别诊断价值
Front Oncol. 2023 Aug 22;13:1186290. doi: 10.3389/fonc.2023.1186290. eCollection 2023.
5
Liver Imaging Reporting and Data System version 2018 category 5 for diagnosing hepatocellular carcinoma: an updated meta-analysis.肝脏影像报告和数据系统 2018 版第 5 类诊断肝细胞癌:一项更新的荟萃分析。
Eur Radiol. 2024 Mar;34(3):1502-1514. doi: 10.1007/s00330-023-10134-z. Epub 2023 Sep 1.
6
Suboptimal performance of LI-RADS v2018 on gadoxetic acid-enhanced MRI for detecting hepatocellular carcinoma in liver transplant candidates.LI-RADS v2018 对钆塞酸增强 MRI 检测肝移植候选者肝细胞癌的性能不佳。
Eur Radiol. 2024 Jan;34(1):465-474. doi: 10.1007/s00330-023-10014-6. Epub 2023 Aug 3.
7
Prospective evaluation of Gadoxetate-enhanced magnetic resonance imaging and computed tomography for hepatocellular carcinoma detection and transplant eligibility assessment with explant histopathology correlation.前瞻性评估钆塞酸增强磁共振成像和计算机断层扫描在肝细胞癌检测和移植适应证评估中的作用,并与离体组织病理学进行相关性分析。
Cancer Imaging. 2023 Feb 25;23(1):22. doi: 10.1186/s40644-023-00532-3.